Apellis and Sobi score another late-stage victory for rare kidney disease drug – Endpoints News

Apellis Pharmaceuticals and Sobi’s kidney disease drug Empaveli reported success in a Phase 3 trial, which could help the treatment keep pace with a …

Sign up to read this article for free.

Get free access to a limited number of articles and opt in to newsletters delivered straight to your inbox.